Private startupCompany profile · informational
insitro
insitro, founded by Daphne Koller, combines machine learning with human cellular data to identify disease drivers and design drug candidates. It has partnerships with Bristol Myers Squibb and Eli Lilly and says it is preparing to move its pipeline into the clinic.
Verified highlights each with its source
- On March 23, 2026, insitro and Bristol Myers Squibb expanded their ALS collaboration to two additional targets, triggering a $10 million milestone payment (company release).
Source: insitro.com ↗ - On Jan. 12, 2026, insitro announced it would acquire antibody-design company CombinAbleAI.
Source: insitro.com ↗ - On Sept. 8, 2026, insitro appointed a Chief Medical Officer to lead its transition to a clinical-stage company.
Source: insitro.com ↗
Sources
- insitro.cominsitro.com
- insitro.cominsitro.com
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
